Published in Cancer Weekly, February 8th, 2005
Nucleonics' submission provides relevant prior art documents that Benitec has not cited in its application, which show that the pending claims are invalid because they lack novelty and/or did not involve an inventive step at the time the patent application was filed. Nucleonics also believes that the claims are unclear and impermissibly extend beyond the scope of the application as filed, and that the application fails to provide adequate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.